Drug & Device Selection in Heart Failure


Book Description

Provides review of the most recent advances in drugs and devices used for the treatment of heart failure, helping clinicians select the best evidence-based therapy for patients. Written by experienced cardiologists from San Francisco and Philadelphia.







Acute Heart Failure


Book Description

For many years, there has been a great deal of work done on chronic congestive heart failure while acute heart failure has been considered a difficult to handle and hopeless syndrome. However, in recent years acute heart failure has become a growing area of study and this is the first book to cover extensively the diagnosis and management of this complex condition. The book reflects the considerable amounts of new data reported and many new concepts which have been proposed in the last 3-4 years looking at the epidemiology, diagnostic and treatment of acute heart failure.




The Breathless Heart


Book Description

This book systematically focuses on central sleep apneas, analyzing their relationship especially with heart failure and discussing recent research results and emerging treatment strategies based on feedback modulation. The opening chapters present historical background information on Cheyne-Stokes respiration (CSR), clarify terminology, and explain the mechanics and chemistry of respiration. Following a description of the physiology of respiration, the pathophysiology underlying central apneas in different disorders and particularly in heart failure is discussed. The similarities and differences of obstructive and central apneas are then considered. The book looks beyond the concept of sleep apnea to daytime CSR and periodic breathing during effort and contrasts the opposing views of CSR as a compensatory phenomenon or as detrimental to the failing heart. The diagnostic tools currently in use for the detection of CSR are thoroughly reviewed, with guidance on interpretation of findings. The book concludes by describing the various forms of treatment that are available for CSR and by explaining how to select patients for treatment.




Disease Control Priorities, Third Edition (Volume 5)


Book Description

Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.




Dilated Cardiomyopathy


Book Description

This open access book presents a comprehensive overview of dilated cardiomyopathy, providing readers with practical guidelines for its clinical management. The first part of the book analyzes in detail the disease’s pathophysiology, its diagnostic work up as well as the prognostic stratification, and illustrates the role of genetics and gene-environment interaction. The second part presents current and future treatment options, highlighting the importance of long-term and individualized treatments and follow-up. Furthermore, it discusses open issues, such as the apparent healing phenomenon, the early prognosis of arrhythmic events or the use of genetic testing in clinical practice. Offering a multidisciplinary approach for optimizing the clinical management of DCM, this book is an invaluable aid not only for the clinical cardiologists, but for all physicians involved in the care of this challenging disease.




Heart Failure


Book Description

Now there is an up-to-date guide for optimizing pharmacologic therapy in treating patients with heart failure. Reflecting current practice at leading medical centers, Heart Failure: Pharmacologic Management provides both the biologic and pathologic underpinnings of each pharmacologic agent in current use. It also supplies detailed discussions of the clinical investigations that support current understanding of the risks and benefits associated with the use of these drugs. Thorough references make the book useful to the novice as well as the experienced clinician. Initial chapters focus on agents that are considered standard care: diuretics ACE inhibitors angiotensin receptor antagonists aldosterone antagonists beta-blockers The discussion moves to agents currently under investigation: Vasopressin antagonists erythropoietin Next, the authors consider some controversial drugs: inotropic agents antiarrhythmic drugs anticoagulants An insightful examination of pharmacogenetics considers: how studies of the genetic profile of patients helps determine which patient populations are most likely to respond to a given class of drugs the potential use of pharmacogenetics to tailor a pharmacologic regimen for maximum benefit and minimum risk Multidrug pharmacy for heart failure therapy An extremely helpful concluding chapter provides a roadmap of drugs with which to approach the patient with heart failure, along with an overview of the skills you need to use it most effectively. This straightforward, step-by-step algorithm will save you countless hours of research and help you make your prescribing decisions with confidence.




Pharmacologic Trends of Heart Failure


Book Description

This volume reviews potential future therapies for heart failure, with a particular focus on ambulatory acute decompensated heart failure and the transitions from therapies in the acute setting to chronic management. Although in the developed world the incidence of and mortality from coronary heart disease and stroke have been declining over the last 15 years, heart failure is increasing in incidence, prevalence and overall mortality, despite advances in the diagnosis and management of the condition. Pharmacologic Trends of Heart Failure builds on the current understanding of pathophysiological mechanisms and insights gained from previous studies of therapeutic interventions. It is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis.




Use of Left Ventricular Assist Devices as Destination Therapy in End-stage Congestive Heart Failure


Book Description

Heart failure is defined as reduced ability of the heart to pump blood and maintain normal bodily function. Heart transplantation is currently the preferred treatment for end-stage heart failure but the supply of donor hearts is insufficient to meet the need and many patients are not eligible for transplantation due to age or comorbid conditions. Implantable mechanical pumps can assist the circulation of blood by the ventricles. Left ventricular assist devices (LVADs) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients awaiting transplant (a bridge to transplant) and as a last resort in patients with refractory heart failure who are not eligible for a heart transplant (destination therapy). In January 2010, the first newer generation, rotary continuous flow ventricular assist device (HeartMate II) was approved by the FDA for destination therapy. Eligibility criteria are essentially the same as those used to select patients for the pivotal clinical trial that included patients with shortness of breath and/or fatigue at rest or during minimal exertion despite treatment with optimal therapy for heart failure associated with a low ejection fraction (




Pharmacologic Approaches to Heart Failure, An Issue of Heart Failure Clinics


Book Description

This issue of Heart Failure Clinics examines the pharmacologic approaches to heart failure: optimizing established therapy with a look toward future agents. Topics include the pathophysiologic foundation for the pharmacologic treatment of heart failure, treatment of heart failure with reducted ejection fraction and preserved ejection fraction, treatment of acute heart failure, investigational treatments, and the role of congestive heart failure medications following left ventricular assist device.